Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B
Sign Up to like & getrecommendations! Published in 2020 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/1076029620946839
Abstract: Hemostatic management is essential for ensuring the safety of patients with hemophilia during surgery. This phase 3, prospective, uncontrolled trial, evaluated hemostatic efficacy, consumption, and safety of a recombinant factor IX concentrate, nonacog gamma (BAX… read more here.
Keywords: nonacog gamma; recombinant factor; previously treated; hemophilia ... See more keywords